Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C

Background/Aims Genetic variants of MHC class I polypeptide-related chain A (MICA) at rs2596542 have been associated with hepatocellular carcinoma. The linkage between serum MICA (sMICA) and liver fibrosis in chronic hepatitis C is elusive. Results Linear regression analysis revealed that sMICA were independently correlated to α-fetoprotein (β: 0.149; 95% confidence interval [CI]: 0.001, 0.003; P = 0.007)and MICA rs2596542 GG genotype (β: 0.209; 95% CI: 0.153, 0.483; P < 0.001). While patients were stratified by MICA genetic variants, advanced fibrosis was the only factor independently correlated to sMICA among A allele carriers (β: 0.234; 95% CI: 0.107, 0.543; P = 0.004) but not among non-A allele carriers. Logistic regression analysis revealed that factors associated with advanced liver fibrosis was sMICA (OR/CI: 2.996/1.428–6.287, P = 0.004) and platelet counts (OR/CI: 0.988/0.982–0.994, P < 0.001) in MICA rs2596542 A allele carriers. sMICA > 50 pg/mL provided a positive predictive value of 72 % in predicting advanced liver fibrosis (F3-4) and of 90% in significant fibrosis (> F2) in MICA rs2596542 A allele carriers. Materials and Methods Serum level and single nucleotide polymorphism at rs2596542 of MICA were tested for the association with liver fibrosis in 319 biopsy proven chronic hepatitis C patients. Conclusions Levels of sMICA were highly correlated to liver disease severity in chronic hepatitis C patients who carried the MICA rs738409 A allele. Patients possessing the genetic predisposition had a higher likelihood of progressed liver fibrosis if they expressed higher sMICA levels.

[1]  Ming‐Lung Yu,et al.  Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment , 2016, EBioMedicine.

[2]  Ming‐Lung Yu,et al.  Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment , 2016, Clinical Cancer Research.

[3]  L. N. Valenti,et al.  DEPDC5 variants increase fibrosis progression in Europeans with chronic hepatitis C virus infection , 2015, Hepatology.

[4]  M. Plummer,et al.  World‐wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma , 2015, Hepatology.

[5]  Aasld Idsa Hcv Guidance Panel Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.

[6]  Ming‐Lung Yu,et al.  Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. , 2015, Journal of hepatology.

[7]  N. Kato,et al.  MICA SNPs and the NKG2D system in virus-induced HCC , 2015, Journal of Gastroenterology.

[8]  T. Asselah,et al.  Genomics and HCV infection: progression of fibrosis and treatment response. , 2012, Journal of hepatology.

[9]  Yusuke Nakamura,et al.  Soluble MICA and a MICA Variation as Possible Prognostic Biomarkers for HBV-Induced Hepatocellular Carcinoma , 2012, PloS one.

[10]  Ming‐Lung Yu,et al.  Chronic hepatitis C infection in the elderly , 2011, The Kaohsiung journal of medical sciences.

[11]  C. Sarrazin,et al.  Multi-center evaluation of the Abbott RealTime HCV assay for monitoring patients undergoing antiviral therapy for chronic hepatitis C. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  Yusuke Nakamura,et al.  Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma , 2011, Nature Genetics.

[13]  M. Manns,et al.  Hepatic expression of A disintegrin and metalloproteinase (ADAM) and ADAMs with thrombospondin motives (ADAM-TS) enzymes in patients with chronic liver diseases. , 2008, Journal of hepatology.

[14]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[15]  M. Sakamoto,et al.  Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. , 1993, The Journal of general virology.

[16]  P. Scheuer,et al.  Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.

[17]  N. Hiramatsu,et al.  Guidelines for the Management of Hepatitis C Virus Infection , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[18]  S. Zeuzem,et al.  EASL Clinical Practice Guidelines: management of hepatitis C virus infection. , 2011, Journal of hepatology.

[19]  S. Bauer,et al.  Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. A. Fleming,et al.  The Acquisition of Data , 1969 .